Porsche SE says it is not considering sale of Volkswagen shares
FRANKFURT (Reuters) - Porsche SE, Volkswagen's biggest shareholder, is not considering selling voting shares in Europe's largest carmaker, the holding firm said on Sunday following a newspaper report that it was weighing such a move.
German tabloid Bild, citing people familiar with the matter, said the Porsche and Piech families that jointly control Porsche SE were considering divesting shares in Volkswagen to free up capital for other investments.
Bild's report said possible scenarios include reducing the stake in Volkswagen's ordinary shares to 45%-50%, from 53.3% at present. According to Reuters calculations, that would raise 1.07 billion to 2.69 billion euros ($1.16 billion-$2.93 billion) at current prices.
"At Porsche SE there are currently no concrete considerations, nor were there in the course of 2024, to divest VW shares," the holding firm said in a statement, adding that any plans to sell VW shares would have to be reported in its accounts.
"There have also been no discussions with investors regarding the sale of VW shares. Porsche SE is committed to its role as a long-term anchor shareholder of Volkswagen AG and is convinced of the Volkswagen Group's potential for increasing value."
Volkswagen declined to comment.
Porsche SE owns 31.9% of Volkswagen's equity and 53.3% of its voting rights, and holds a blocking minority in the untraded voting shares in Porsche AG, the luxury sportscar maker that was listed in 2022.
Volkswagen and Porsche form Porsche SE's so-called core investments, and the holding firm last year said that in the long-term it would not rule out "a possible reallocation" between the two as well as its smaller portfolio investments.
Porsche SE earlier this month disclosed substantial impairments on its two biggest holdings, 19.9 billion euros on Volkswagen and 3.4 billion euros on Porsche AG.
($1 = 0.9192 euros)
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
27 minutes ago
- Yahoo
Fabrizio Romano Confirms Florian Wirtz to Liverpool is ‘100% Done'
Liverpool Beat Rivals to Sign Florian Wirtz in Stunning Transfer Coup Liverpool have pulled off a sensational coup in the transfer market, with the signing of Florian Wirtz now '100% done,' according to transfer expert Fabrizio Romano. The Bayer Leverkusen star, widely regarded as one of the brightest attacking midfielders in Europe, has chosen Anfield as his next destination, turning down strong interest from Bayern Munich, Real Madrid and Manchester City. Advertisement Romano confirmed on Tuesday that 'Liverpool verbally agree deal in principle with Bayer Leverkusen for package reaching €150m add-ons included,' adding that the 'player side already agreed two weeks ago with move now imminent' and that 'Wirtz set for medical and contract signing.' The 22-year-old German international, currently on holiday, is expected to complete his move following a medical once the transfer window reopens on 16 June. This delay is due to FIFA Club World Cup regulations. Behind the Deal: Slot's Role and Player Decision This wasn't a transfer engineered overnight. Initial speculation linked Wirtz with Manchester City, especially after he was spotted in England with his parents, who also serve as his representatives. However, those assumptions were quickly flipped on their head. German reports suggested that the Wirtz entourage travelled not to Manchester, but to Merseyside. Advertisement Arne Slot, fresh off a Premier League-winning debut campaign, is believed to have played a pivotal role in securing the player's decision. During his UK visit, Wirtz reportedly held a direct conversation with the Liverpool manager. That meeting appears to have been decisive. The report explains that 'a conversation with the Liverpool boss convinced him to choose a move to Anfield over going to Bayern Munich.' Slot's project, vision and playing style are said to have swayed the attacking midfielder, who has long been touted as the spiritual successor to Mesut Özil in the German national team setup. Photo: IMAGO Mixed Reports but Deal Remains on Track Despite Romano's strong declarations, some sources remain slightly more cautious. A contradictory update came from another senior journalist, who stated there was 'no agreement yet' between the clubs. However, even that statement confirmed that Liverpool and Leverkusen were in the 'final stages' of negotiations. Advertisement Romano doubled down on his position, clarifying that 'I told you two days ago (Tuesday) that the agreement is done. I can confirm that the agreement is done. You can consider Wirtz as a Liverpool player.' The delay in any official confirmation is, according to Romano, entirely due to Wirtz being on holiday. Once he returns, the medical and contract signing are set to follow swiftly. Photo: IMAGO Strategic Timing Ahead of Window Opening With the summer transfer window closed until 16 June, Liverpool and Bayer Leverkusen have time to finalise the structure of the deal, which is said to be complex due to the size of the package involved. Advertisement This breathing room could prove beneficial, as clubs look to iron out technicalities and payment schedules before the move is rubber-stamped. The final valuation, reportedly reaching €150 million including add-ons, represents a record-breaking commitment from Liverpool. But if Wirtz can translate his Bundesliga brilliance to the Premier League, it may well be a bargain in the long run. Our View – Anfield Index Analysis This is seismic. The sort of signing Liverpool fans used to dream about but rarely saw happen unless a star was being sold. To beat Bayern, Real Madrid and Man City to Florian Wirtz speaks volumes not just about Liverpool's pulling power, but also about the Slot effect. Arne Slot hasn't just won the league, he's clearly winning hearts and minds off the pitch too. Advertisement Wirtz is a generational talent. His ability to glide past players, his intelligence between the lines and his fearless creativity are exactly what this team needs to evolve again. While fans are rightly still emotional after the Klopp era, Slot seems to be building something both sustainable and exciting. There's a buzz growing. The thought of Wirtz linking up with Salah, Szoboszlai and Diaz in a fluid front four will have fans counting down the days until pre-season. The fee might be huge, but so was the statement. This is not a rebuild, it's a reload. Credit to Fabrizio Romano for staying consistent on this story. His updates have been the most confident throughout and, once again, he appears to have been proven right.
Yahoo
an hour ago
- Yahoo
Novo Nordisk ramps up obesity fight, advances amycretin to Phase III
Novo Nordisk is progressing both subcutaneous and oral versions of amycretin into Phase III trials for patients with obesity and who are overweight. Following a positive end-of-Phase II meeting, Novo Nordisk shared that regulatory authorities have approved the therapy to proceed. The company plans to initiate the trial in adults who are overweight or with obesity in Q1 2026. Executive vice president for development at Novo Nordisk, Martin Lange said: 'We are very pleased that the feedback from regulatory authorities has allowed us to take subcutaneous and oral amycretin in weight management to Phase III. We are excited about the amycretin molecule, and this marks an important step forward. We look forward to sharing more information on the design of the Phase III programme.' In a Phase Ib/IIa study (NCT06064006), amycretin, a glucagon-like peptide-1 (GLP-1) and amylin receptor co-agonist, showed weight-loss outcomes of up to 22% in 36 weeks. This was higher than seen by the company's blockbuster therapy Wegovy (semaglutide), which demonstrated a body weight change of 14% at week 36 in a Phase II study. The Phase Ia/IIb study investigated three doses of once-weekly subcutaneous amycretin in 125 patients who are overweight or with obesity. The primary endpoint was treatment-emergent adverse events (TEAEs), with Novo Nordisk reporting that the most common events were gastrointestinal, and the majority were mild to moderate in severity. If successful in a Phase III trial, GlobalData anticipates that amycretin will receive approval for adults with overweight or obesity in Q4 2030 in the US, followed by approval in the EU in Q1 2031. GlobalData is the parent company of Clinical Trials Arena. Novo Nordisk has signed a $812m partnership with Deep Apple Therapeutics to access novel compounds, not GLP-1RAs, for obesity and other diseases. As well as this, the company has also listed two new studies for CagriSema, another candidate in its pipeline. The company recently announced underwhelming data from a Phase III trial, which, while meeting its primary endpoint, fell short of the 25% weight loss promise. Following all these updates, Novo Nordisk's share price has now increased, making it the most valuable company in Europe once again. It has a market cap of $359.28bn compared to German software company SAP at $359bn. Novo Nordisk's flagship semaglutide, marketed as Wegovy in weight loss and Ozempic in type 2 diabetes, is forecast to make $49bn in sales in 2030, according to GlobalData. Its main competitor, Eli Lilly's tirzepatide, marketed as Zepbound in weight loss and Mounjaro in type 2 diabetes, is projected to reach sales of $60.8bn. Lilly's drug proved to have higher efficacy than Novo Nordisk's in a head-to-head study between the pair. "Novo Nordisk ramps up obesity fight, advances amycretin to Phase III" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Germany's multibillion dollar spending surge to focus on railways
Germany's massive infrastructure spending surge will focus on reviving the country's now-decrepit rail system. Germany's once-vaunted railways are now one of the worst-performing in Europe, with just 72% of German trains arriving within 10 minutes of their scheduled time. The bulk of this year's share of a 12-year, $570 billion investment announced in March will go to rail, in an attempt to end the country's economic stagnation: The government is betting that improving intercity commuting will strengthen both productivity and the political mood, and help stave off the far right. Much of the rest will go to Germany's crumbling road system, especially bridges: Experts estimate that 16,000 bridges, including 4,000 on the autobahns, urgently need repair or replacement.
